GUANGZHOU, China, Jan. 17, 2026 /PRNewswire/ — Recently, GAC Energy has released its 2025 Ecological Service Report, highlighting strong advances in ultra-fast charging technology, nationwide network deployment, and V2G innovation under the GAC Group’s “2⁶ Energy Action” strategy – the strategic plan launched by GAC Group to develop a comprehensive, vertically integrated new energy vehicle (NEV) industry chain and ecosystem. By the end of 2025, GAC Energy operated 23,274 self-operated charging piles across 31 provinces and 211 cities, including 17,577 DC piles. It had 1,956 charging stations serving 8.92 million users and delivering 1.43 billion kWh of electricity, leading the industry in 1000V high-voltage fast-charging piles.

In ultra-fast charging technology, GAC Energy continued to strengthen its technology and operations throughout the year. Ultra-fast charging piles were upgraded to 640 kW, with individual gun capability reaching 720 kW and 800 A. In May, an AI-powered smart management cloud platform was introduced, enabling real-time control and automated operation of charging facilities, raising equipment online availability to 99.2% and significantly enhancing service stability.

The charging network has entered a phase of accelerated expansion. By March 2025, GAC Energy’s charging services had surpassed 100 million cumulative sessions, with the user base exceeding 5 million and 24/7 service ensuring worry-free travel. In July, total charging volume exceeded 1 billion kWh. In September, the number of self-operated charging piles took the industry lead by surpassing 20,000. By November, the charging network covered China’s major cities and main travel corridors, with more than 1,800 self-operated charging stations deployed, ensuring that users in core urban areas can conveniently reach a station within 1 km.

In the V2G field, GAC Energy completed China’s first private car owner V2G discharge order in August 2025 and, in September, built the country’s largest V2G microgrid, with an average daily discharge of more than 11,000 kWh per station. By the end of 2025, GAC Energy’s national V2G discharge exceeded 1.35 million kWh, with power trading surpassing 130 million kWh and cumulative carbon reduction reaching 3.43 million tons, contributing to a low-carbon, sustainable energy ecosystem.

Entering 2026, GAC Energy is accelerating its momentum—driving the evolution of smarter, faster, and greener charging solutions, and building a secure, sustainable energy ecosystem that powers the future of mobility.

LAS VEGAS, Jan. 17, 2026 /PRNewswire/ — At CES 2026, Flowtica was not the loudest presence on the show floor. Over the course of the week, however, the Singapore-based AI company became one of the most closely watched, drawing sustained attention from media, investors, and industry observers.

That attention has now translated into availability. Following its appearance as a CES 2026 Innovation Award Honoree, Flowtica has officially opened sales of Flowtica Scribe, its AI recording pen that quietly stood out in a field dominated by phone-dependent and screen-heavy solutions.

Flowtica Scribe did not make its first public appearance at CES. The product launched on Kickstarter several months earlier, where it attracted thousands of users and established early validation. CES marked a different stage for the company. The focus shifted away from introduction and toward closer examination, with many observers asking whether the idea could hold up beyond early enthusiasm.

Throughout the exhibition, Flowtica’s booth at Eureka Park became a steady meeting point for investors and journalists. Conversations rarely centered on specifications or feature lists. Instead, discussions focused on a more fundamental question: whether AI recording tools are beginning to converge on forms that genuinely fit into professional life.

Flowtica’s answer was visible in its choice of form. By embedding AI into a pen, an object already accepted in boardrooms, consultations, investor meetings, and sales conversations, the company avoided many of the social and practical frictions that continue to limit phone-based recorders. The result was a device that felt less like a new category of gadget and more like a natural extension of existing behavior.

This restraint is deliberate. Flowtica Scribe is designed to remain unobtrusive, with no screen and no demand for user attention during conversations. Recording, organization, and interpretation take place quietly in the background, allowing users to remain focused on the discussion itself. Among on-site observers, this approach positioned Flowtica as one of the more pragmatic entrants in an increasingly crowded AI recording market.

Hardware, however, represents only part of Flowtica’s differentiation. The company places equal emphasis on what happens after recording ends. Its AI functions as a continuously evolving insight system that can operate autonomously while remaining responsive to clear user guidance when needed. Over time, it adapts to individual working rhythms and priorities, shifting the emphasis from capturing everything to identifying what truly matters.

Rather than simply storing conversations, Flowtica helps determine which moments should be retained, revisited, and translated into next actions. Key insights are designed to integrate naturally with existing productivity tools, including calendars and task systems, allowing them to fit into established workflows rather than compete with them.

As interest in Flowtica Scribe built during CES, one question surfaced repeatedly. When would the product be available beyond the show floor?

With sales now officially open through Flowtica’s website, the company moves from exhibition attention to real-world deployment. For Flowtica, this moment appears less like a conclusion and more like a transition, from being observed to being used.

As the AI recording market continues to mature, competition is shifting away from novelty and early adoption toward durability. The defining question is no longer whether a system can record conversations, but whether it can remain useful over time.

Flowtica enters this next phase with an approach that is measured and quietly confident, placing its bet not on spectacle, but on long-term relevance.

MELBOURNE, Australia and INDIANAPOLIS, Jan. 16, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Biopsy of the Prostate Avoidance Stratification Study), a Phase 3 trial to  evaluate the use of Telix’s commercial PSMA-PET^[1] imaging agents, Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) and Gozellix® (kit for the preparation of gallium Ga 68 gozetotide injection) in the initial prostate cancer diagnosis setting. The dose was administered under the supervision of Dr. Brian Mazzarella at Urology Austin and supplied by RLS Radiopharmacies.

BiPASS™ is the first study designed to gain marketing authorization for ⁶⁸Ga-PSMA-PET^[2] imaging in the pre-biopsy setting. The prospective, open-label Phase 3 trial will enroll 250 patients across sites in the U.S. and Australia. The study aims to determine whether combining MRI^[3] with Illuccix/Gozellix ⁶⁸Ga-PSMA-11 PET can improve diagnostic accuracy and reduce unnecessary biopsies compared to current standard practice. Men with elevated PSA^[4] often proceed from an inconclusive MRI to template prostate biopsy. This procedure is stressful and unpleasant, can lead to complications^[5] and frequently proves to be of no benefit to the patient^[6].

In the U.S., more than one million prostate biopsies are performed annually, yet up to 75% are negative^[6], and one in four patients declines the physician recommendation of receiving a biopsy^[7]. The objective of BiPASS™ is to demonstrate improved lesion detection and patient stratification by integrating non-invasive molecular Illuccix/Gozellix ⁶⁸Ga-PSMA-11 PET imaging early in the diagnostic pathway, to enable biopsy de-escalation or, alternatively, greater biopsy precision when administered.

If the BiPASS™ study achieves its primary objectives, it could lead to a reduction in unnecessary biopsies, improved patient experience, and a significant expansion of access to precision imaging for patients with suspected prostate cancer, potentially increasing the use of ⁶⁸Ga-PSMA-11 PET in a large new patient population.

Dr. Mazzarella, Vice President of Research for Urology America, said, “We’re excited to participate in the BiPASS trial at Urology Austin, which brings together promising technologies and emerging trends in patient care.  If BiPASS is successful in meeting its primary endpoint, it could eliminate the need for biopsy—reducing risks, side effects, and costs—and improve decision-making for providers and patients.”

Kevin Richardson, Chief Executive Officer, Telix Precision Medicine, added, “Illuccix and Gozellix are already transforming how clinicians treat and manage prostate cancer. By initiating this trial, we are reinforcing Telix’s commitment to patient centricity, clinical innovation, and industry leadership—with the goal of eliminating invasive biopsy.”

About BiPASS™

BiPASS™ (ClinicalTrials.gov ID: NCT07052214) leverages promising clinical findings from the PRIMARY^[8] and PRIMARY2^[9] studies, which demonstrated that MRI combined with ⁶⁸Ga-PSMA-11 PET can better define or rule out prostate cancer and guide active surveillance before invasive biopsy. Professor Louise Emmett, Principal Investigator for PRIMARY, serves on the BiPASS™ Steering Committee and as an Investigator on the study.

About Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection)

Illuccix, after radiolabeling with ⁶⁸Ga, is indicated for PET scanning of PSMA positive lesions in men with prostate cancer who have suspected metastasis and are candidates for initial definitive therapy, those with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level, and for selection of patients who are indicated for PSMA-directed therapy as described in the prescribing information of the therapeutic products.

About Gozellix® (kit for the preparation of gallium Ga 68 gozetotide injection)

Gozellix, after radiolabeling with ⁶⁸Ga, is indicated for PET scanning of PSMA positive lesions in men with prostate cancer who have suspected metastasis and are candidates for initial definitive therapy, and those with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Illuccix, Telix’s first generation PSMA-PET imaging agent, has been approved in multiple markets globally. Gozellix has been approved by the U.S. FDA^[10]. Illuccix and Gozellix have not received regulatory approval for initial diagnosis of prostate cancer in any jurisdiction.

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

Telix Investor Relations (U.S.)  

Annie Kasparian 
Telix Pharmaceuticals Limited 
Director Investor Relations and Corporate Communications 
Email: annie.kasparian@telixpharma.com 

Media Contact

Eliza Schleifstein
917.763.8106 (Mobile)
Eliza@schleifsteinpr.com

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including the planned NDA resubmission for TLX101-Px and the planned BLA resubmission for TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

LOS ANGELES, Jan. 17, 2026 /PRNewswire/ — From January 6–8, 2026, Arspura, a premium smart home appliance brand focused on healthier kitchen air, presented its latest IQV™ innovations at CES 2026 and hosted a three-day brand program in Las Vegas. Centered on exclusive technology, respiratory wellness, and user experience, the program brought together experts, product leaders, and real customers to spotlight how better cooking environments can start with better indoor air management.

At the heart of Arspura’s CES showcase was its proprietary IQV™ Dynamic Particulate Capture Technology, designed to capture cooking smoke, grease particles, and odor at the source—helping reduce the common “smoke escape” problem many households experience with traditional ventilation. Through live demonstrations and deep-dive sessions, Arspura emphasized a clear brand promise for modern kitchens: Cook freely, breathe freely.

To watch highlights from Arspura’s CES 2026 showcase, visit:

https://www.youtube.com/watch?v=owPq9B5GcLE

Day 1: Uncovering the Kitchen’s Invisible Health Threats

On the first day of CES 2026, Arspura kicked off its brand program with a keynote by Professor Francesca Dominici of the Harvard T.H. Chan School of Public Health (Professor of Biostatistics & Data Science; Professor of Environmental Health).

Drawing on her research on air pollution and health, she highlighted the risks of fine particulate matter (PM2.5) and emphasized that even low-level exposure can make people sick. She noted that PM2.5 can be particularly hazardous for older adults, people with existing health conditions, and individuals with asthma, and stressed that preventing cooking-related PM2.5 from dispersing indoors and reducing exposure at the source is crucial for family health.

Reflecting on this message, Arspura underscored its commitment to helping more households—especially those with asthma or nasal sensitivities—cook with greater comfort by reducing smoke and odor irritation, so more people can truly cook freely and breathe freely.

Day 2: Redefining a New Standard for Smoke-Free Cooking

On the second day, Arspura’s product manager led a technical session explaining how IQV™ airflow design works together with high-airspeed capture (up to 13 m/s) to deliver high capture performance with minimal smoke escape. The presentation framed Arspura’s approach as more than a product: a combination of technology and daily usability designed to make healthy cooking feel effortless.

Arspura also welcomed a special on-site visit and interview from media figure Yang Lan, who explored the booth experience and shared positive feedback on IQV™ technology and the IQV Hood concept—particularly its relevance for people sensitive to cooking fumes who want a more comfortable kitchen environment.

Day 3: Bringing Healthy Kitchen Living Into Everyday Ease

Arspura closed out CES 2026 with strong momentum, earning five awards during the show. To cap the three-day program, the brand invited its first group of IQV Hood users for a face-to-face sharing session, paired with immersive, hands-on demonstrations. Through interactive experiences and practical use scenarios, attendees felt firsthand how the product can deliver “health protection” and “easy cleaning” simultaneously, translating the idea of a healthier kitchen into tangible everyday value.

Passionate home cooks also shared how they had previously tried multiple traditional range hoods yet still struggled with smoke escape and lingering odors, while Arspura’s IQV™ performance provided noticeably improved smoke capture and deodorization—making cooking more enjoyable and inspiring friends and family to upgrade after seeing the results.

What’s Next for Arspura

Backed by strong recognition at CES 2026 and reinforced by firsthand user stories, Arspura’s IQV™ showcase signaled a growing shift toward kitchen ventilation solutions that prioritize both health and everyday usability. Building on this momentum, Arspura will continue to develop smarter, cleaner-air technologies for modern homes.

For more information, visit arspura.com.

In the news release, NYSE Content Advisory: Pre-Market Update + Singapore Software Firm TechCreate Rings NYSE Bell after IPO, issued 16-Jan-2026 by New York Stock Exchange over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows:

NYSE Content Advisory: Pre-Market Update + Singapore Software Firm TechCreate Rings NYSE Bell after IPO

NEW YORK, Jan. 16, 2026 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins.  

Kristen Scholer delivers the pre-market update on January 16^th

• Equities are higher this morning, lifted by tech enthusiasm, with chipmakers leading gains after Taiwan Semiconductor’s upbeat outlook and news of a U.S.–Taiwan trade deal involving at least $250B in Taiwanese chip and tech investment in U.S. production
• The stock rally is broadening, as the small‑cap Russell 2000 climbs too; experts say more stocks could benefit in the new year thanks to continued economic resilience.
• Tune in to NYSE Live at 9 a.m. ET as Tech‑Create Group celebrates its NYSE American IPO; CEO Heng Hai Lim will join to discuss the company’s real‑time payments, digital banking, and cybersecurity solutions.

Opening Bell
TechCreate Group celebrates its recent IPO

Closing Bell
Legendary New York Knicks Alumni tip-off the franchise’s Alumni Homecoming Weekend

Click here to download the NYSE TV App

Correction: The video has been updated in this version of the release. 

Video – https://mma.prnasia.com/media2/2863581/NYSE_Market_Update_Jan_16.mp4

TAIPEI, Jan. 17, 2026 /PRNewswire/ — GIGABYTE, the world’s leading computer brand, strengthens its strategic partnership with NVIDIA by unveiling a new generation of flagship products built on NVIDIA’s latest platform at CES 2026. The lineup spans new GeForce RTX™ 5090 graphics cards, powerful GeForce RTX™ laptops with built-in NVIDIA Studio, and G-SYNC Compatible gaming monitors, leveraging NVIDIA’s cutting-edge GPU, RTX™ AI, and display technologies. Building on this foundation, GIGABYTE layers its own advanced cooling, system-control, and display innovations to deliver a uniquely powerful and polished experience for both gamers and creators.

Leading the graphics card lineup, the AORUS GeForce RTX™ 5090 INFINITY is powered by the NVIDIA Blackwell architecture, leveraging GeForce RTX™ 50 Series capabilities to power next-level RTX gaming and AI computing. Equipped with a massive level of AI horsepower, the RTX 50 Series enables new experiences and next-level graphics fidelity. Multiply performance with NVIDIA DLSS 4, generate images at unprecedented speed, and unleash creativity with NVIDIA Studio. To support the GPU in performing at its full potential, GIGABYTE reinforces the design with the WINDFORCE HYPERBURST Cooling System, combining a separated PCB design, patented Hawk fans, and an additional Overdrive Fan for extra cooling headroom under heavy loads. The result is more sustained peak performance, wrapped in a premium showcase design featuring a circular heatsink, a die-cast metal backplate, and iconic RGB Halo lighting.

For mobile users, the AORUS MASTER 16 brings GeForce RTX™ performance powered by NVIDIA Blackwell for gaming and creator workloads, backed by NVIDIA Studio and Studio Drivers to ensure stability in leading creative apps. GIGABYTE elevates the experience with WINDFORCE Infinity EX thermal design rated for 230W thermal power to sustain performance in a thin form factor, and GiMATE, GIGABYTE’S exclusive AI agent that consolidates key system settings into clear, mode-based choices and workflow-friendly shortcuts. Together, NVIDIA Studio’s reliability and GIGABYTE’s GiMATE usability help users get RTX™ gaming performance and smoother creative throughput without constantly tuning profiles.

Rounding out the ecosystem, the G-SYNC Compatible GIGABYTE MO34WQC36, MO32U24, and MO27Q28GR gaming monitors validate a baseline VRR experience by matching display refresh rate to GPU frame rate for tear-free, reduced-stutter gameplay. Building on gameplay smoothness delivered by NVIDIA G-SYNC, GIGABYTE adds its exclusive Tactical Features, a suite of built-in tools designed to sharpen precision and control. For example, Tactical Switch 2.0 enables one-click switching between resolutions and aspect ratios such as 4:3 or 5:4, offering greater flexibility for different game types. Additionally, Aim Stabilizer intelligently inserts black frames to reduce motion blur, and Game Assist overlays such as a custom crosshair and timer for additional competitive edge.

By strengthening collaboration with NVIDIA across graphics cards, laptops, and displays, this lineup leverages GIGABYTE’s leadership in cooling, system control, and display tuning to translate platform innovation into real-world advantages for everyday AI gaming and creation. Learn more at: https://bit.ly/GIGABYTE_Event_CES_2026_NV